OS according to the TP53 and CDKN2A allelic status in DLBCL. (A) Overall survival (OS) probability in the entire lymphoma population (n = 114). (B) OS probability in the subgroup of patients treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP–like regimens (n = 78). T53/CDKN2A score indicates patients without any deletion (score 0), 1 deletion (score 1), or 2 deletions (score 2).